$AUPH Breaking Out On Drug News

April 21, 2017
By

Relavent info-“Both doses of voclosporin at 48 weeks demonstrated continued improvement over the control group across multiple dimensions. Notably, the voclosporin groups demonstrated statistically significantly improved speed and rates of CR and PR. Of the patients that achieved CR at 24 weeks, in the low-dose voclosporin group, 100% remained in CR at 48 weeks, which demonstrates durability of clinical response. Proteinuria levels and reduction in SLEDAI scores, which include non-renal measures of lupus activity, also continued to significantly separate over time versus the control group. Additional analyses are ongoing and will be presented at future medical and scientific meetings. No unexpected safety signals were observed and voclosporin was generally well-tolerated, with the nature of adverse events consistent with what is expected of patients suffering from highly active LN while undergoing immunomodulation-based therapy.”

Leave a Reply

Your email address will not be published. Required fields are marked *

Quick Reference Videos

Click on links below for an Introduction to Dan's Mentoring Group and a Recent Advance Class Meeting -

btm022613

btm021213b

bmt2_8